Eli Lilly (LLY) EPS (Weighted Average and Diluted) (2012 - 2026)
Eli Lilly posted quarterly EPS (Weighted Average and Diluted) of $8.26 for Q1 2026, up 169.93% year-on-year from $3.06 in Q1 2025, and up 11.77% on a QoQ basis from $7.39 in Q4 2025.
Eli Lilly (LLY) has 15 years of EPS (Weighted Average and Diluted) data on file, last reported at $8.26 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 169.93% year-over-year to $8.26; the trailing twelve-month figure through Mar 2026 stood at $28.15 (up 129.05% YoY), and the FY2025 full-year result was $22.95, up 95.99% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $8.26, up from $7.39 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $8.26 in Q1 2026 and bottomed at -$0.06 in Q3 2023.
- The 5-year median for EPS (Weighted Average and Diluted) is $2.42 (2023), against an average of $3.27.
- The widest annual swing landed in 2023, when EPS (Weighted Average and Diluted) slumped 103.73%; it then surged 1883.33% in 2024.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $2.14 in 2022, then advanced by 13.08% to $2.42 in 2023, then surged by 101.65% to $4.88 in 2024, then jumped by 51.43% to $7.39 in 2025, then gained by 11.77% to $8.26 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $8.26 (Q1 2026), $7.39 (Q4 2025), and $6.21 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 8.26 |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 0.39 |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -1.72 |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 3.34 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.61 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 0.47 |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 1.31 |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.26 |
| Dec 31, 2025 | 7.39 |
| Sep 30, 2025 | 6.21 |
| Jun 30, 2025 | 6.29 |
| Mar 31, 2025 | 3.06 |
| Dec 31, 2024 | 4.88 |
| Sep 30, 2024 | 1.07 |
| Jun 30, 2024 | 3.28 |
| Mar 31, 2024 | 2.48 |
| Dec 31, 2023 | 2.42 |
| Sep 30, 2023 | -0.06 |
| Jun 30, 2023 | 1.95 |
| Mar 31, 2023 | 1.49 |
| Dec 31, 2022 | 2.14 |
| Sep 30, 2022 | 1.61 |
| Jun 30, 2022 | 1.05 |
| Mar 31, 2022 | 2.10 |
| Dec 31, 2021 | 1.89 |
| Sep 30, 2021 | 1.22 |
| Jun 30, 2021 | 1.53 |
| Mar 31, 2021 | 1.49 |
| Dec 31, 2020 | 2.32 |
| Sep 30, 2020 | 1.33 |
| Jun 30, 2020 | 1.55 |
| Mar 31, 2020 | 1.60 |
| Dec 31, 2019 | 1.64 |
| Sep 30, 2019 | 1.37 |
| Jun 30, 2019 | 1.44 |
| Mar 31, 2019 | 0.57 |
| Dec 31, 2018 | 1.10 |
| Sep 30, 2018 | 1.07 |
| Jun 30, 2018 | -0.22 |
| Mar 31, 2018 | 1.16 |
| Dec 31, 2017 | -1.58 |
| Sep 30, 2017 | 0.53 |
| Jun 30, 2017 | 0.95 |
| Mar 31, 2017 | -0.10 |
| Dec 31, 2016 | 0.73 |
| Sep 30, 2016 | 0.73 |
| Jun 30, 2016 | 0.71 |
| Mar 31, 2016 | 0.41 |
| Dec 31, 2015 | 0.45 |
| Sep 30, 2015 | 0.75 |
| Jun 30, 2015 | 0.56 |
| Mar 31, 2015 | 0.50 |
| Dec 31, 2014 | 0.40 |
| Sep 30, 2014 | 0.47 |
| Jun 30, 2014 | 0.68 |
| Mar 31, 2014 | 0.68 |
| Dec 31, 2013 | 0.67 |
| Sep 30, 2013 | 1.11 |
| Jun 30, 2013 | 1.11 |
| Mar 31, 2013 | 1.42 |
| Dec 31, 2012 | 0.74 |
| Sep 30, 2012 | 1.18 |
| Jun 30, 2012 | 0.83 |
| Mar 31, 2012 | 0.91 |